NCT05748405View on ClinicalTrials.gov

Phase 1/2 Trial of AEF0217 in Participants With Down Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 15, 2022

Primary Completion Date

October 7, 2024

Study Completion Date

October 7, 2024

Conditions
Down Syndrome
Interventions
DRUG

Placebo

Matching Tablets

DRUG

AEF0217

Tablets of 100 mcg AEF0217

Trial Locations (3)

28006

Unidad de Adultos con Síndrome de Down, Hospital de La Princesa, Madrid

08003

Hospital del Mar Medical Research Institute (IMIM),, Barcelona

08025

Sant Pau Memory Clinic, Hospital de la Santa Creu i Sant Pau, Barcelona

Sponsors

Lead Sponsor

Aelis Farma
All Listed Sponsors
collaborator

European Commission

OTHER

lead

Aelis Farma

INDUSTRY

NCT05748405 - Phase 1/2 Trial of AEF0217 in Participants With Down Syndrome | Biotech Hunter | Biotech Hunter